Drew Alexander
Dallas, TXNPI 1194819763
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,993 of the $117,063 with a category attached, or 76.9%. 9 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 53.7% of the total.
Across 291 payments — averaging $402.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$63K
- Ironshore Pharmaceuticals Inc.$50K
- Otsuka America Pharmaceutical, Inc.$3K
- Axsome Therapeutics, Inc.$297
- Sanofi Pasteur Inc.$120
- AbbVie$112
- plus $149 from 3 others
What the payments were for
- Consulting fees$7,0786%
- Speaking & faculty fees$89,99377%
- Travel & lodging$14,22612%
- Food & beverage$5,7665%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 142 | $62,833 |
| Ironshore Pharmaceuticals Inc. | 129 | $50,385 |
| Otsuka America Pharmaceutical, Inc. | 5 | $3,166 |
| Axsome Therapeutics, Inc. | 8 | $297 |
| Sanofi Pasteur Inc. | 1 | $120 |
| AbbVie | 1 | $112 |
| Tris Pharma Inc | 1 | $93 |
| Adlon Therapeutics L.p. | 3 | $43 |
| Noven Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $305 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.